Repligen Corporation

Repligen Corporation, a for-profit manufacturer of bioprocessing and laboratory filtration equipment headquartered in Waltham, Massachusetts, sells tangential flow filtration (TFF) systems, XCell Lab controllers, and pharmaceutical single-use consumables to federal health and defense agencies as a prime contractor (82% of recent awards), competing full-and-open without set-aside designations on the majority of work. The company operates through two named subsidiaries: C Technologies, Inc. and Spectrum Lifesciences, LLC, both manufacturers of goods.

Repligen's federal footprint centers on biomedical research infrastructure and COVID-19 vaccine and therapeutic development. The company's largest award by magnitude is a $14.4 million Total Small Business purchase order from the Office of the Assistant Secretary for Preparedness and Response, awarded September 30, 2021, for pharmaceutical consumables expansion — single-use bags, assemblies, and tubing — with ultimate completion August 31, 2035. Representative prime work includes a $174.6 thousand purchase order from the Food and Drug Administration (May 28, 2026) for XCell Lab Controllers and Accessories, a $48.7 thousand Defense Health Agency order (February 2, 2024) for a KR2i TFF system and installation support for the Walter Reed Army Institute of Research's bioproduction facility, and a $34.4 thousand FDA purchase order (September 16, 2024) for a KR2i tangential flow filtration unit. A single $30.5 thousand TFF system award from the National Institute of Allergy and Infectious Diseases (March 14, 2022) carried a Total Small Business set-aside.

Customer concentration is heavily skewed to the Office of the Assistant Secretary for Preparedness and Response, which accounts for $14.4 million of the $15 million combined potential value across all awards (99% of dollars), though the Food and Drug Administration leads by award count with five orders totaling $359 thousand. The National Institutes of Health (through NIAID and the National Cancer Institute), the Defense Health Agency, the Department of the Navy, and the Department of Veterans Affairs round out the active customer set, each with one to two awards under $100 thousand. Repligen places two task orders under the GSA Multiple Award Schedule. In its subcontractor role, Repligen delivers tangential flow filtration systems and automated XCell Dual ATF2 equipment to Becton, Dickinson and Company on NIAID vaccine research task orders (January 29, 2024) and provides goods or services to Leidos on an Inflation Reduction Act research support services contract (December 21, 2023).

Recent activity averages less than one award per year across the 2021–2026 period, with four awards in 2024 and one in 2026. Only one award (the $175 thousand XCell Lab Controllers order) faces ultimate completion inside the next twenty-four months and therefore recompete exposure. The company's capability portfolio is concentrated in biological product manufacturing (8 awards) and analytical laboratory instrument manufacturing (3 awards), with primary procurement category focus on laboratory equipment and supplies.